The Patient-Centric Synergy of Pharmaceutical CDMO and CRO Collaborations
.png)
Pharmaceutical collaborations are nothing new to the industry. Increasingly complex drug development programs, calls for supply chain resiliency, and the involvement of all key stakeholders throughout a drug’s development lifecycle are pushing contract development and manufacturing organisations to partner with their counterparts in research.
Deals between pharmaceutical CDMOs and CROs have resulted in billions of dollars in M&A transactions. 48 deals between pharmaceutical CDMOs and CROs were made in the first half of 2021 alone. The CMO industry counted 479 deals between 2018–2022 of either whole companies or individual facilities.
The benefits of these partnerships and M&A decisions include:
Efficient speed-to-market processes
The drug discovery, development, and commercial pipeline will benefit from fewer disruptions and transfers of samples, products, and technologies between companies. Ultimately, a pharmaceutical CDMO and CRO collaboration aims to provide ample product availability on shorter timescales.
Clinical trial support
The organisation and orchestration of a clinical trial will benefit from clear and concise communication between pharmaceutical CDMOs and CROs in partnership. Expanded geographic reaches offered by both organisations can increase access to expertise in specialised therapeutic areas and establish patient-centred trial frameworks. Decentralised clinical trials are also on the rise as patients become more invested in their healthcare treatment journeys.
An industry-wide mindset shift
"Companies and their leadership have to be very intentional about the values that they are embedding into the organisation,” states Brenda Bruker, Thermo Fisher Scientific’s Executive Director, Integrated Supply and Delivery Services. “A shared vision and values from the top and across all teams is critical. That’s part of what we do – we drive that level of communication and training across the organisation to ensure that everybody understands their role in the process, even down to each individual and what role they can play in maximising the customer experience.”
This idea of optimising a patient’s experience with the drug they are taking is not a new idea. Patient-centricity has been a main topic of discussion throughout the pharmaceutical supply chain. Pharmaceutical players who want to position themselves as leaders in the industry must begin to consider the patient as integral to the design and manufacture of their product. As the industry blurs the operational designations between CDMOs and CROs, an intentional collaboration between the two can result in the patient-centric future the industry has been discussing for years.
Our latest Trend Report in collaboration with Thermo Fisher Scientific Inc. takes a look at how collaborations between CDMOs and CROs have developed and where they intend to go. We also examine how such partnerships can ultimately lead the drive towards patient-centricity within the pharmaceutical industry, paving the way for a true nexus between patient and Big Pharma.

Related News
-
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance